Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Running, not enrolling · Phase 3
Conditions studied: Hepatocellular Carcinoma
In brief
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
Key facts
- Study ID
- NCT03755791
- Run by
- Exelixis
- People needed
- 837
- Starts
- 2018-06-10
- Expected to finish
- 2026-07-31
- Last updated by the study team
- 2025-12-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Exelixis Clinical Site #159 — Tucson, Arizona, United States
- Exelixis Clinical Site #44 — La Jolla, California, United States
- Exelixis Clinical Site #112 — Los Angeles, California, United States
- Exelixis Clinical Site #200 — Orange, California, United States
- Exelixis Clinical Site #2 — Rialto, California, United States
- Exelixis Clinical Site #207 — San Diego, California, United States
- Exelixis Clinical Site #109 — San Francisco, California, United States
- Exelixis Clinical Site #54 — San Francisco, California, United States
- Exelixis Clinical Site #58 — Washington D.C., District of Columbia, United States
- Exelixis Clinical Site #191 — Miami, Florida, United States
- Exelixis Clinical Site #4 — Atlanta, Georgia, United States
- Exelixis Clinical Site #195 — Chicago, Illinois, United States
- Exelixis Clinical Site #120 — Chicago, Illinois, United States
- Exelixis Clinical Site #6 — Baltimore, Maryland, United States
- Exelixis Clinical Site #7 — Burlington, Massachusetts, United States
- Exelixis Clinical Site #11 — Kansas City, Missouri, United States
- Exelixis Clinical Site #5 — Kansas City, Missouri, United States
- Exelixis Clinical Site #8 — St Louis, Missouri, United States
- Exelixis Clinical Site #1 — Las Vegas, Nevada, United States
- Exelixis Clinical Site #14 — New Brunswick, New Jersey, United States
- Exelixis Clinical Site #76 — Albuquerque, New Mexico, United States
- Exelixis Clinical Site #12 — Chapel Hill, North Carolina, United States
- Exelixis Clinical Site #39 — Toledo, Ohio, United States
- Exelixis Clinical Site #176 — Portland, Oregon, United States
- Exelixis Clinical Site #208 — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.